KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Assets Average (2016 - 2025)

Historic Assets Average for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $1.4 billion.

  • Emergent BioSolutions' Assets Average fell 378.43% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 378.43%. This contributed to the annual value of $1.6 billion for FY2024, which is 3560.68% down from last year.
  • Per Emergent BioSolutions' latest filing, its Assets Average stood at $1.4 billion for Q3 2025, which was down 378.43% from $1.4 billion recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Assets Average high stood at $3.1 billion for Q1 2023, and its period low was $1.4 billion during Q1 2025.
  • For the 5-year period, Emergent BioSolutions' Assets Average averaged around $2.3 billion, with its median value being $2.6 billion (2023).
  • As far as peak fluctuations go, Emergent BioSolutions' Assets Average skyrocketed by 2556.01% in 2021, and later plummeted by 4070.08% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Assets Average (Quarter) stood at $2.9 billion in 2021, then rose by 4.07% to $3.0 billion in 2022, then crashed by 38.7% to $1.9 billion in 2023, then fell by 22.84% to $1.4 billion in 2024, then increased by 0.37% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.4 billion during Q1 2025.